Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer

Kenichi OgataDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, JapanCorrespondence[email protected]
[email protected]

http://orcid.org/0000-0002-3001-6981

Hiroshi TakamoriDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Naoki UmezakiDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Taisuke YagiDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Katsuhiro OgawaDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Nobuyuki OzakiDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Hiromitsu HayashiDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Hideyuki TanakaDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Yoshiaki IkutaDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

Koichi DoiDepartment of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

show all

References

Sirohi B, Philip DS, Shrikhande SV. Regorafenib: carving a niche in the crowed therapeutic landscape. Expert Rev Anticancer Ther. 2013;13(4):383–393.
Web of Science ®Google Scholar
Ranpura V, Hapai S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487–494.10.1001/jama.2011.51
PubMed Web of Science ®Google Scholar
Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a mata-analysis. Lancet Oncol. 2009;10(6):559–568.10.1016/S1470-2045(09)70112-3
PubMed Web of Science ®Google Scholar
Badgwell BD, Camp ER, Freig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577–582.
PubMed Web of Science ®Google Scholar
Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, et al. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol. 2009;14(6):513–517.10.1007/s10147-009-0911-6
PubMed Web of Science ®Google Scholar
Adenis A, Kotecki N, Decanter G, Clisant S, Penel N. Regorafenib use as a possible cause of intestinal perforation. Acta Oncol. 2013;52(8):1789–1790.10.3109/0284186X.2013.835070
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date